Literature DB >> 16265611

Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV.

Anuradha Balasubramanian1, Margaret Koziel, Jerome E Groopman, Ramesh K Ganju.   

Abstract

We have previously shown that hepatocytes exposed to hepatitis C virus (HCV) and human immunodeficiency virus (HIV) envelope proteins undergo apoptosis. In this article, we further elucidate the signaling mechanisms that mediate this effect. We found that, in human hepatocellular carcinoma (HepG2) cells, HCV E2 protein and HIV glycoprotein (gp) 120 significantly up-regulated the Fas ligand (FasL) and enhanced the formation of the Fas death-inducing signaling complex downstream of Fas receptor activation. Moreover, after stimulation with HCV E2 and HIV gp120, enhanced expression of caspases 2 and 7 and increased caspase 3 activity were observed. In addition, we showed up-regulation of the proapoptotic molecule Bid and its association with caspase 8 after treatment with these envelope proteins. We also found that HCV E2 and HIV gp120 induced a partial translocation of Bid to the mitochondria, which resulted in the release of cytochrome C and the apoptosis-inducing factor. Thus, the results of this study suggest that FasL and Bid play an important role in HCV and HIV envelope protein-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265611     DOI: 10.1086/429493

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  HIV and liver disease forum: conference proceedings.

Authors:  Kenneth E Sherman; Marion Peters; Margaret James Koziel
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

2.  HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity.

Authors:  Nagako Akeno; Jason T Blackard; Yaron Tomer
Journal:  J Autoimmun       Date:  2008-09-16       Impact factor: 7.094

3.  Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study.

Authors:  José Antonio Mata-Marín; Jesús Gaytán-Martínez; Bernardo Horacio Grados-Chavarría; José Luis Fuentes-Allen; Carla Ileana Arroyo-Anduiza; Alfredo Alfaro-Mejía
Journal:  Virol J       Date:  2009-10-30       Impact factor: 4.099

4.  Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.

Authors:  M Guzmán-Fulgencio; J Berenguer; M García-Álvarez; D Micheloud; J C López; J Cosín; I Fernández de Castro; P Catalán; P Miralles; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-26       Impact factor: 3.267

5.  Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.

Authors:  Subbiah Elankumaran; Daniel Rockemann; Siba K Samal
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 6.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 7.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

Review 8.  Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.

Authors:  Jag H Khalsa; Glenn Treisman; Elinore McCance-Katz; Ellen Tedaldi
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

Review 9.  Underlying pathophysiology of HCV infection in HIV-positive drug users.

Authors:  Anuradha Balasubramanian; Jerome E Groopman; Ramesh K Ganju
Journal:  J Addict Dis       Date:  2008

10.  Low-level HIV infection of hepatocytes.

Authors:  Ling Kong; Walter Cardona Maya; Maria E Moreno-Fernandez; Gang Ma; Mohamed T Shata; Kenneth E Sherman; Claire Chougnet; Jason T Blackard
Journal:  Virol J       Date:  2012-08-09       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.